The earnings call highlighted significant growth in North American and EMEA markets, particularly in strategic products like Crysvita and Poteligeo. However, this was offset by declines in overall revenue and interim profit due to restructuring costs and challenges in the Japanese market. While there were strong performances in certain segments and promising R&D developments, the financial declines and restructuring challenges resulted in a mixed sentiment.

Company Guidance -

Q3 2025

During the call, Kyowa Kirin Co., Ltd. provided financial guidance for Q2 of the fiscal year ending December 31, 2025. The company reported a revenue of JPY230.7 billion, marking a 1% decrease compared to the previous year, largely due to business restructuring in the APAC region and NHI price reductions in Japan. Core operating profit fell by 21% to JPY35 billion, attributed to a decrease in gross profit and a 7% rise in R&D expenses. Interim profit saw a significant drop of 57% to JPY16.3 billion, impacted by JPY9.4 billion in special voluntary retirement payments. Despite these declines, the company remains optimistic about achieving its full-year plan, with revenue and gross profit at 48% of the forecast and core operating profit at 44%. Sales in North America grew by 12%, driven by Crysvita and Poteligeo, which saw increases of 11% and 15%, respectively. The company is also advancing its R&D pipeline, with promising developments in products like Ziftomenib and rocatinlimab, which are undergoing crucial trials and FDA submissions.

Growth in North America and EMEA

Sales in North America increased by JPY9.6 billion, or 12%, in real terms excluding forex impact. Crysvita and Poteligeo grew 11% and 15% respectively in local currency terms.

Strong Performance of Strategic Products

Crysvita continues to grow throughout North America, EMEA, and Japan, with revenues up 10%, or JPY8.9 billion YoY. Poteligeo also continued to grow, increasing its sales by JPY2.6 billion or 14% over the previous year.

Significant Increase in Libmeldy/Lenmeldy Sales

Sales of Libmeldy/Lenmeldy began to be booked in the US and increased significantly, showing a JPY3 billion or 206% increase.

Progress in Ziftomenib Development

Ziftomenib, an oral small molecule menin inhibitor for AML, showed promising results in the KOMET-001 and KOMET-007 trials, with a favorable safety profile and high efficacy rates, leading to a submission for FDA approval.

Kyowa Kirin Co (JP:4151) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

JP:4151 Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 31, 2025	2025 (Q3)	36.52 / -	34.44	―	―	―
Jul 31, 2025	2025 (Q2)	31.84 / 19.40	43.5	-55.40% (-24.10)
May 01, 2025	2025 (Q1)	26.11 / 11.78	27.26	-56.79% (-15.48)		―
Feb 06, 2025	2024 (Q4)	23.90 / 7.86	51.41	-84.71% (-43.55)		―
Oct 31, 2024	2024 (Q3)	35.39 / 34.44	59.35	-41.97% (-24.91)		―
Aug 01, 2024	2024 (Q2)	28.47 / 43.50	16.53	163.16% (+26.97)		―
May 07, 2024	2024 (Q1)	28.50 / 27.26	23.74	14.83% (+3.52)		―
Feb 07, 2024	2023 (Q4)	53.93 / 51.41	8.11	533.91% (+43.30)		―
Nov 01, 2023	2023 (Q3)	61.25 / 59.35	26.41	124.73% (+32.94)		―
Aug 03, 2023	2023 (Q2)	26.07 / 16.53	35.31	-53.19% (-18.78)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

JP:4151 Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	¥2565.50	¥2597.00	+1.23%
May 01, 2025	¥2198.03	¥2211.36	+0.61%
Feb 06, 2025	¥2226.67	¥2212.84	-0.62%
Oct 31, 2024	¥2449.95	¥2462.15	+0.50%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Kyowa Kirin Co Ltd (JP:4151) report earnings?

Kyowa Kirin Co Ltd (JP:4151) is schdueled to report earning on Oct 31, 2025, TBA (Confirmed).

What is Kyowa Kirin Co Ltd (JP:4151) earnings time?

Kyowa Kirin Co Ltd (JP:4151) earnings time is at Oct 31, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Kyowa Kirin Co Ltd stock?

The P/E ratio of Kyowa Kirin Co is N/A.

What is JP:4151 EPS forecast?

JP:4151 EPS forecast for the fiscal quarter 2025 (Q3) is 36.52.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing